Manlius, NY, United States of America

Helen Gray Haggerty




Average Co-Inventor Count = 19.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: **Innovative Contributions of Helen Gray Haggerty in Biopharmaceuticals**

Introduction

Helen Gray Haggerty, an accomplished inventor based in Manlius, NY, has made notable advancements in the field of biopharmaceuticals. With a total of five patents to her name, her work primarily revolves around the production of therapeutic proteins, significantly impacting medical treatments.

Latest Patents

Among her recent patents, two key inventions stand out: "Compositions and Methods for Producing a Composition," and "Carbohydrate Content of CTLA4 Molecules." These patents present novel methods utilizing mammalian cells to produce recombinant CTLA4-Ig and its variants. They also outline formulations and methods for mass-producing and purifying CTLA4-Ig, aiming to enhance therapeutic efficacy in clinical settings.

Career Highlights

Helen has been instrumental in driving innovation at Bristol-Myers Squibb Company, where she continues to apply her expertise in biopharmaceuticals. Her dedicated research and development efforts have led to critical advancements in the production and quality of biotherapeutics.

Collaborations

Throughout her career, Helen has collaborated with noted professionals such as Kirk J. Leister and Eugene J. Schaefer. Their combined expertise has fostered a research environment that emphasizes innovation and effective problem-solving, leading to groundbreaking discoveries in the field.

Conclusion

Helen Gray Haggerty's contributions to the field of biopharmaceuticals underscore her significance as an inventor. Her innovative patents not only reflect her commitment to scientific advancement but also highlight the potential for improved patient outcomes through her pioneering work.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…